HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT).

Abstract
CC49 is a clinically validated antibody with specificity for TAG-72, a carbohydrate epitope that is overexpressed and exposed on the cell surface in a large fraction of solid malignancies. We constructed a single-chain fragment (scFv) based on CC49 and fused it to beta-lactamase (BLA). Following optimization of the scFv domain by combinatorial consensus mutagenesis (CCM) for increased expression and stability, we characterized the protein variant for binding, in vivo pharmacokinetics (PK), and antitumor efficacy. The fusion protein TAB2.5 possessed a similar binding specificity relative to the parent antibody CC49. TAB2.5 also showed prolonged retention (T(1/2) = 36.9 h) in tumor-bearing mice with tumor/plasma ratios of up to 1000. Preliminary evaluation of TAB2.5, in combination with a novel prodrug, GC-Mel, resulted in significant efficacy in a colorectal xenograft tumor model and supports the utility of the protein as an agent for tumor-selective prodrug activation.
AuthorsRalph F Alderson, Brian E Toki, Martin Roberge, Wei Geng, Joshua Basler, Regina Chin, Amy Liu, Roanna Ueda, Douglas Hodges, Enrique Escandon, Tianling Chen, Tessi Kanavarioti, Lilia Babé, Peter D Senter, Judith A Fox, Volker Schellenberger
JournalBioconjugate chemistry (Bioconjug Chem) 2006 Mar-Apr Vol. 17 Issue 2 Pg. 410-8 ISSN: 1043-1802 [Print] United States
PMID16536473 (Publication Type: Evaluation Study, Journal Article)
Chemical References
  • Antibiotics, Antineoplastic
  • Antibodies, Neoplasm
  • Antineoplastic Agents, Alkylating
  • Antineoplastic Agents, Phytogenic
  • B72.3 antibody
  • Cephalosporins
  • Drug Carriers
  • Immunoglobulin Fragments
  • Immunoglobulin Variable Region
  • Nitrogen Mustard Compounds
  • Prodrugs
  • Recombinant Fusion Proteins
  • TAB2.5 fusion protein
  • glutaryl C-Mel
  • Irinotecan
  • Doxorubicin
  • beta-Lactamases
  • Melphalan
  • Camptothecin
Topics
  • Animals
  • Antibiotics, Antineoplastic (therapeutic use)
  • Antibodies, Neoplasm (chemistry, genetics, metabolism, therapeutic use)
  • Antineoplastic Agents, Alkylating (chemistry, metabolism, therapeutic use)
  • Antineoplastic Agents, Phytogenic (therapeutic use)
  • Camptothecin (analogs & derivatives, therapeutic use)
  • Cephalosporins (chemistry, metabolism, therapeutic use)
  • Colorectal Neoplasms (drug therapy, metabolism, pathology)
  • Doxorubicin (therapeutic use)
  • Drug Carriers (chemistry, metabolism)
  • Drug Delivery Systems
  • Female
  • Humans
  • Immunoglobulin Fragments (genetics, metabolism)
  • Immunoglobulin Variable Region (genetics, metabolism)
  • Irinotecan
  • Melphalan (chemistry, metabolism, therapeutic use)
  • Mice
  • Mice, Nude
  • Molecular Structure
  • Neoplasm Transplantation
  • Nitrogen Mustard Compounds (chemistry, metabolism, therapeutic use)
  • Prodrugs (chemistry, metabolism, therapeutic use)
  • Recombinant Fusion Proteins (chemistry, genetics, metabolism, therapeutic use)
  • beta-Lactamases (chemistry, genetics, metabolism, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: